Status:

COMPLETED

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program

Lead Sponsor:

Santen Inc.

Conditions:

Non-Infectious Uveitis of the Posterior Segment of the Eye

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have partici...

Detailed Description

This is a multicenter, open-label, extension study of intravitreal injections of the 440 μg dose of DE-109 in subjects with non-infectious uveitis of the posterior segment who received any dose of DE-...

Eligibility Criteria

Inclusion

  • Participated in the SAKURA study
  • Received clinical benefit from treatment in the SAKURA study
  • Ability to sign informed consent and attend all study visits

Exclusion

  • Uveitis of infectious etiology
  • Implanted device
  • Suspected or confirmed central nervous system or ocular lymphoma
  • Uncontrolled glaucoma
  • Significant ocular disease
  • Intravitreal injections in the past 60 days
  • Intraocular surgery or treatment
  • Ocular or periocular infection
  • History of herpetic infection
  • Toxoplasmosis or toxoplasmosis scar
  • Ocular malignancy
  • Vitrectomy
  • Allergy or hypersensitivity to study drug
  • Participation in other uveitis device clinical trials within 30 days
  • Any recent systemic condition/infection
  • Immunosuppressive therapy or immunocomprimised
  • Cytomegalovirus infection
  • Malignancy in remission
  • Females who are pregnant or lactating and who are not using adequate contraceptive
  • Medical marijuana or illegal drug use
  • Systemic saroidosis
  • Therapeutic radiation to the head or neck

Key Trial Info

Start Date :

September 29 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 27 2017

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT02251938

Start Date

September 29 2014

End Date

November 27 2017

Last Update

February 12 2020

Active Locations (25)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (25 locations)

1

Phoenix, Arizona, United States

2

Sacramento, California, United States

3

Golden, Colorado, United States

4

Tampa, Florida, United States